Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections," while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported disappointing results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 27-28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. regarding allegations of securities fraud and unlawful business practices following a significant drop in share price after its IPO [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Fermi and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until March 6, 2026, to request to be appointed as Lead Plaintiff if they purchased Fermi securities related to its IPO [2]. Group 2: IPO and Subsequent Developments - Fermi completed its IPO on October 1, 2025, offering 32.5 million shares at a price of $21.00 per share [4]. - On December 12, 2025, Fermi announced the termination of a $150 million Advance in Aid of Construction Agreement for its Project Matador data center, which negatively impacted investor confidence and share price [4].

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by March 2, 2026 [2]. - The lawsuit pertains to actions taken by Agilon and certain officers or directors that may have violated securities laws [2]. Group 2: Company Background and Recent Events - On August 4, 2025, Agilon announced the resignation of Steven Sell as President, CEO, and Director, coinciding with the release of its second-quarter financial results [4]. - The Executive Chair of Agilon indicated that industry challenges were more severe than anticipated, leading to the suspension of the company's full-year 2025 financial guidance [4]. - Following these announcements, Agilon's stock price dropped by $0.94, or 51.52%, closing at $0.88 per share on August 5, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Bitdeer Technologies Group for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves allegations against Bitdeer and certain officers and/or directors regarding securities fraud [2]. - Investors who purchased Bitdeer securities during the Class Period have until February 2, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Performance - On November 10, 2025, Bitdeer reported unaudited financial results for Q3 2025, showing earnings per share of -$1.28, which was significantly below the consensus estimate of -$0.22 [4]. - Following the earnings report, Bitdeer's stock price dropped by $2.63, or 14.9%, closing at $15.02 per share on November 11, 2025 [4]. - The company also disclosed significant delays in the development of its next-generation Seal 04 ASIC chip [4].

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation and certain officers for alleged violations of federal securities laws during the Class Period from July 25, 2025, to August 14, 2025, seeking to recover damages for investors [1]. Company Overview - SLM Corporation, commonly known as Sallie Mae, primarily originates and services private education loans (PELs) to students and their families, emphasizing its "high-quality" PELs and loss mitigation programs [4]. - The company classifies its PELs as in repayment when customers are making interest-only or fixed payments, or when they have entered full principal and interest repayment status [5]. Allegations and Misleading Statements - The lawsuit claims that SLM's executives made materially false and misleading statements regarding the company's business and operations, which artificially inflated the prices of SLM's securities during the Class Period [6]. - Specifically, it is alleged that SLM was experiencing a significant increase in early-stage delinquencies, contradicting the company's public assurances about the stability of its delinquency rates and the effectiveness of its loss mitigation programs [6]. Impact of Delinquency Rates - Delinquency rates on SLM's PELs are a critical metric for investors, as the cost to service a delinquent borrower is significantly higher than servicing a current or in-school borrower [5]. - A report from TD Cowen on August 14, 2025, indicated that July 2025 delinquencies were up 49 basis points month-over-month, which was worse than the expected seasonal performance, leading to a significant drop in SLM's stock price by $2.67 per share, or 8.09% [7].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves allegations against Alexandria and certain officers and/or directors regarding securities fraud [2]. - Investors have until January 26, 2026, to request to be appointed as Lead Plaintiff if they purchased Alexandria securities during the Class Period [2]. Group 2: Financial Performance - On October 27, 2025, Alexandria reported disappointing financial results for Q3 2025, including a reduction in full-year 2025 funds from operations (FFO) guidance [4]. - The company cited lower occupancy rates, slower leasing activity, and a significant real estate impairment charge of $323.9 million, with $206 million related to its Long Island City property [4]. Group 3: Market Reaction - Following the announcement of the financial results, Alexandria's stock price dropped by $14.93 per share, or 19.17%, closing at $62.94 per share on October 28, 2025 [5].

Core Viewpoint - A class action lawsuit has been filed against Gauzy Ltd. regarding allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The class action lawsuit involves Gauzy and certain officers and/or directors accused of engaging in securities fraud or other unlawful business practices [2]. - Investors have until February 6, 2026, to request to be appointed as Lead Plaintiff if they purchased or acquired Gauzy securities during the Class Period [2]. Group 2: Financial Performance and Impact - On November 14, 2025, Gauzy announced a delay in releasing its financial results for Q3 2025 due to insolvency proceedings ordered by the Commercial Court of Lyon, France, affecting three subsidiaries [4]. - Following the announcement of the insolvency proceedings, Gauzy's stock price dropped by $1.35 per share, or 33.58%, closing at $2.67 per share on the same day [4].

Core Viewpoint - A class action lawsuit has been filed against Jayud Global Logistics Ltd. for alleged securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit claims that Jayud and certain officers/directors engaged in securities fraud [2]. - Investors have until January 19, 2026, to request to be appointed as Lead Plaintiff if they purchased Jayud securities during the Class Period [2]. - A copy of the Complaint is available at Pomerantz LLP's website [2]. Group 2: Allegations Against Jayud - The complaint alleges that Jayud failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [4]. - It is claimed that insiders used offshore or nominee accounts to facilitate the dumping of shares during a price inflation campaign [4]. - Jayud's public statements and risk disclosures allegedly omitted information about false rumors and artificial trading activity affecting the stock price [4]. - As a result, the positive statements made by the defendants regarding the company's business and prospects were misleading and lacked a reasonable basis [4].

Core Viewpoint - Block & Leviton is investigating Travere Therapeutics, Inc. for potential securities law violations following a significant drop in share price after the FDA extended the review timeline for a key drug application [1][2]. Group 1: Company Overview - Travere Therapeutics, Inc. experienced a trading halt after its shares fell over 30% on January 13, 2026, due to the FDA's extension of the review timeline for the supplemental New Drug Application for FILSPARI [2]. - The FDA set a new PDUFA target action date of April 13, 2026, citing that additional responses from Travere constituted a major amendment and required further data to assess clinical benefit [2]. Group 2: Investigation Details - Block & Leviton is examining whether Travere Therapeutics adequately disclosed the risks associated with the review extension and if prior communications regarding the regulatory timeline were misleading [2][4]. - The firm is considering filing an action to recover losses for investors who have been affected by the decline in share value [4]. Group 3: Investor Eligibility - Any individual who purchased common stock of Travere Therapeutics and has experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they have sold their investment [3]. Group 4: Whistleblower Information - Individuals with non-public information about Travere Therapeutics are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 5: Firm's Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].